132 related articles for article (PubMed ID: 36442383)
21. Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer.
Bazhenova L; Kish J; Cai B; Caro N; Feinberg B
Cancer Treat Res Commun; 2022; 33():100637. PubMed ID: 36162323
[TBL] [Abstract][Full Text] [Related]
22. Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review.
Juarez-Garcia A; Sharma R; Hunger M; Kayaniyil S; Penrod JR; Chouaïd C
Lung Cancer; 2022 Apr; 166():205-220. PubMed ID: 35316754
[TBL] [Abstract][Full Text] [Related]
23. Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.
Bowman L; Tiu R; Smyth EN; Willard MD; Li L; Beyrer J; Han Y; Singh A
Clin Lung Cancer; 2021 Jan; 22(1):32-41.e1. PubMed ID: 33221173
[TBL] [Abstract][Full Text] [Related]
24. Outcomes in Patients With Non-small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy.
Sun L; Davis CW; Hwang WT; Jeffries S; Sulyok LF; Marmarelis ME; Singh AP; Berman AT; Feigenberg SJ; Levin W; Ciunci CA; Bauml JM; Cohen RB; Langer CJ; Aggarwal C
Clin Lung Cancer; 2021 Jan; 22(1):58-66.e3. PubMed ID: 33279417
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Galli G; De Toma A; Pagani F; Randon G; Trevisan B; Prelaj A; Ferrara R; Proto C; Signorelli D; Ganzinelli M; Zilembo N; de Braud F; Garassino MC; Lo Russo G
Lung Cancer; 2019 Nov; 137():38-42. PubMed ID: 31526910
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
27. Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience.
Phan C; Jespersen F; Weipert C; Li T; Yoneda KY
Ther Adv Respir Dis; 2022; 16():17534666221135324. PubMed ID: 36346075
[TBL] [Abstract][Full Text] [Related]
28. Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
Kongnakorn T; Sarri G; Freitag A; Marczell K; Kazmierska P; Masters E; Pawar V; Zhang X
Pharmacoeconomics; 2022 Feb; 40(2):183-201. PubMed ID: 34595671
[TBL] [Abstract][Full Text] [Related]
29. The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
Jacobi O; Landman Y; Reinhorn D; Icht O; Sternschuss M; Rotem O; Finkel I; Allen AM; Dudnik E; Goldstein DA; Zer A
Oncology; 2021; 99(9):555-561. PubMed ID: 34247166
[TBL] [Abstract][Full Text] [Related]
30. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Popat S; Brustugun OT; Cadranel J; Felip E; Garassino MC; Griesinger F; Helland Å; Hochmair M; Pérol M; Bent-Ennakhil N; Kruhl C; Novello S
Lung Cancer; 2021 Jul; 157():9-16. PubMed ID: 34051652
[TBL] [Abstract][Full Text] [Related]
31. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy-based combinations in metastatic NSCLC.
Desai A; Peters S
Cancer Treat Rev; 2023 May; 116():102545. PubMed ID: 37030062
[TBL] [Abstract][Full Text] [Related]
33. Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer.
Danesi V; Massa I; Foca F; Delmonte A; Crinò L; Bronte G; Ragonesi M; Maltoni R; Manunta S; Cravero P; Andrikou K; Priano I; Balzi W; Gentili N; Burke T; Altini M
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139641
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.
McLouth LE; Gabbard J; Levine BJ; Golden SL; Lycan TW; Petty WJ; Weaver KE
J Palliat Med; 2023 Jun; 26(6):831-836. PubMed ID: 36912809
[No Abstract] [Full Text] [Related]
35. Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy.
Dickson NR; Beauchamp KD; Perry TS; Roush A; Goldschmidt D; Edwards ML; Blakely LJ
J Patient Rep Outcomes; 2024 Feb; 8(1):23. PubMed ID: 38416270
[TBL] [Abstract][Full Text] [Related]
36. Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents.
Abraham P; Kish JK; Korytowsky B; Radtchenko J; Singh P; Shaw J; Feinberg B
J Med Econ; 2020 Feb; 23(2):125-131. PubMed ID: 31581922
[No Abstract] [Full Text] [Related]
37. Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens.
Tompkins WP; Hwang WT; Yang YX; Singh A; Ciunci C; D'Avella C; Aggarwal C; Cohen RB; Langer CJ; Mamtani R; Marmarelis ME
Clin Lung Cancer; 2023 Sep; 24(6):558-562.e2. PubMed ID: 37451933
[TBL] [Abstract][Full Text] [Related]
38. Telephone interventions for symptom management in adults with cancer.
Ream E; Hughes AE; Cox A; Skarparis K; Richardson A; Pedersen VH; Wiseman T; Forbes A; Bryant A
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD007568. PubMed ID: 32483832
[TBL] [Abstract][Full Text] [Related]
39. Unmet Care Needs and Financial Hardship in Patients With Metastatic Non-Small-Cell Lung Cancer on Immunotherapy or Chemoimmunotherapy in Clinical Practice.
McLouth LE; Nightingale CL; Levine BJ; Burris JL; McDougall JA; Lycan TW; Gabbard J; Ruiz J; Farris M; Blackstock AW; Grant SC; Petty WJ; Weaver KE
JCO Oncol Pract; 2021 Aug; 17(8):e1110-e1119. PubMed ID: 33539182
[TBL] [Abstract][Full Text] [Related]
40. The patient experience of ABVD treatment in Hodgkin lymphoma: a retrospective cohort study of patient-reported distress.
Tarnasky AM; Troy JD; LeBlanc TW
Support Care Cancer; 2021 Sep; 29(9):4987-4996. PubMed ID: 33576877
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
